Abstract:figure legend This study investigated the effects of fetal hyperglucagonaemia on insulin secretion and pancreatic development in late‐gestation sheep. Fetal sheep were infused with low (GCG‐5) or high (GCG‐50) doses of glucagon, resulting in reduced plasma insulin and amino acid concentrations, with no changes in plasma glucose. Chronic exposure to impaired glucose‐stimulated insulin secretion (GCG‐50 only), decreased β‐ and α‐cell proliferation, reduced pancreatic mass and lowered islet area (GCG‐50 only). These findings demonstrate that elevated fetal glucagon negatively impacts fetal pancreatic development and insulin secretion, potentially increasing the risk of metabolic diseases later in life. Fetal glucagon concentrations are elevated in the presence of a compromised intrauterine environment, as in cases of placental insufficiency and perinatal acidaemia. Our objective was to investigate the impact of late gestation fetal hyperglucagonaemia on in vivo insulin secretion and pancreatic islet structure. Chronically catheterized late gestation fetal sheep received an intravenous infusion of glucagon at low (5 ng/kg/min; GCG‐5) or high (50 ng/kg/min; GCG‐50) concentrations or a vehicle control (CON) for 8–10 days. Glucose‐stimulated fetal insulin secretion (GSIS) was measured following 3 h (acute response) and 8–10 days (chronic response) of experimental infusions. Insulin, glucose and amino acid concentrations were measured longitudinally. The pancreas was collected at the study end for histology and gene expression analysis. Acute exposure (3 h) to GCG‐50 induced a 3‐fold increase in basal insulin concentrations with greater GSIS. Meanwhile, chronic exposure to both GCG‐5 and GCG‐50 decreased basal insulin concentrations 2‐fold by day 8–10. Chronic GCG‐50 also blunted GSIS at the study end. Fetal amino acid concentrations were decreased within 24 h of GCG‐5 and GCG‐50, while there were no differences in fetal glucose. Histologically, GCG‐5 and GCG‐50 had lower β‐ and α‐cell proliferation, as well as lower α‐cell mass and pancreas weight, while GCG‐50 had lower islet area. This study demonstrates that chronic glucagon elevation in late gestation fetuses impairs β‐cell proliferation and insulin secretion, which has the potential to contribute to later‐life diabetes risk. We speculate that the action of glucagon in lower circulating fetal amino acid concentrations may have a suppressive effect on insulin secretion. Key points We have previously demonstrated in a chronically catheterized fetal sheep model that experimentally elevated glucagon in the fetus impairs placental function, reduces fetal protein accretion and lowers fetal weight. In the present study, we further characterized the effects of elevated fetal glucagon on fetal physiology with a focus on pancreatic development and β‐cell function. We show that experimentally elevated fetal glucagon results in lower β‐ and α‐cell proliferation, as well as decreased insulin secretion after 8−10 days of glucagon infusion. These results have important implications for β‐cell reserve and later‐life predisposition to diabetes.

Exogenous GLP-1 stimulates TCA cycle and suppresses gluconeogenesis and ketogenesis in late-fasted northern elephant seals pups

Increases in Thyroid Hormone‐Mediated Plasma Glucose Does Not Stimulate Insulin Secretion in Prolonged‐Fasting Northern Elephant Seal Pups

Oxylipin responses to fasting and insulin infusion in a large mammalian model of fasting-induced insulin resistance, the northern elephant seal

Prolonged food deprivation increases mRNA expression of deiodinase 1 and 2, and thyroid hormone receptor β-1 in a fasting-adapted mammal

Response to Dietary L-glutamine Supplementation in Weaned Piglets: a Serum Metabolomic Comparison and Hepatic Metabolic Regulation Analysis.

Intestinal gluconeogenesis controls the neonatal development of hypothalamic feeding circuits

Chronic late-gestation hypoglycemia upregulates hepatic PEPCK associated with increased PGC1α mRNA and phosphorylated CREB in fetal sheep

Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice

Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake Via P38 Alpha Map Kinase-Mediated, Nitric Oxide-Dependent Mechanisms in Conscious Dogs with Dilated Cardiomyopathy

Response to Weaning and Dietary L-glutamine Supplementation: Metabolomic Analysis in Piglets by Gas Chromatography/mass Spectrometry.

A non-traditional model of the metabolic syndrome: the adaptive significance of insulin resistance in fasting-adapted seals

Metabolic Switch from Glycogen to Lipid in the Liver Maintains Glucose Homeostasis in Neonatal Mice.

GLP-1-derived nonapeptide GLP-1(28-36)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice.

1612-P: Energetic Contributions of GLP1 and GCGR Activity in GLP1/GIP/GCGR Triagonism

Effect of GLP-1 receptor agonist on lipolysis in adipose tissue of obese mice and its underlying mechanism

Chronic late gestation fetal hyperglucagonaemia results in lower insulin secretion, pancreatic mass, islet area and beta‐ and α‐cell proliferation

Active Metabolite of Glp-1 Mediates Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs with Dilated Cardiomyopathy

The Roles of Insulin, Glucagon, and Free Fatty Acids in the Regulation of Ketogenesis in Dogs

1898-P: Colonic Short-Chain Fatty Acids Lower Endogenous Glucose Production

The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction

Rapid Hypoxia‐Induced Upregulation of Glutathione‐Related Genes May Protect Elephant Seal Endothelial Cells Against Oxidative Stress